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Does Mitral Valve Repair Improve Survival in
Secondary Mitral Regurgitation?*Robert O. Bonow, MD, MSS econdary or functional mitral regurgitation(MR) continues to challenge cardiologists andcardiac surgeons in crafting optimal patient
management strategies. This form of MR is distinctly
different from primary forms of MR arising from
diseases of the mitral leaﬂets in terms of pathophysi-
ology, natural history, outcomes, and treatment
options, and current practice guidelines provide
separate recommendations for primary and second-
ary MR (1,2). The indications for intervention in sec-
ondary MR are more ambiguous than those for
primary MR.
Secondary MR is the result of left ventricular (LV)
remodeling, and the presence and severity of second-
ary MR reﬂect the extent of underlying LV dilationSEE PAGE 875and dysfunction (3). The presence of even mild
degrees of secondary MR (with small regurgitant
volumes that would be well tolerated in a patient
with mitral valve prolapse) identiﬁes patients with
LV dysfunction who have a higher mortality risk
than those without MR (4–6). However, in an in-
dividual patient with LV dysfunction, it is difﬁcult
to ascertain whether secondary MR is merely a
marker of a sicker left ventricle or whether it is a
contributor to the sicker left ventricle. Hence, it
remains uncertain whether secondary MR should
be a target for therapy (7). Unlike severe primary
MR, in which surgical elimination of the regur-
gitant volume can completely transform an* Editorials published in JACC: Cardiovascular Interventions reﬂect the
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contents of this paper to disclose.otherwise ominous natural history, the results of
surgery for secondary MR are unpredictable in
improving patient outcomes.
Surgery for secondary MR has never been tested
against medical therapy for LV dysfunction in a pro-
spective randomized trial. However, studies com-
paring outcomes of patients with secondary MR
treated with mitral valve repair and those treated
medically, using propensity matching, have failed to
demonstrate an advantage of surgery in improving
survival (8,9). In addition, unlike surgical repair of
primary MR (10), valve repair for secondary MR is
often not durable (11,12), presumably because of
progression of the underlying myocardial disease.
Because secondary MR is primarily a disease of
the heart muscle, not the valve itself, the appro-
priate initial target for treating secondary MR is the
left ventricular dysfunction (1,2). Evidence-based
medical and device therapies for LV systolic
dysfunction that favorably reverse-remodel the left
ventricle are associated with reduction in severity
of secondary MR. This is particularly the case for
treatment with beta-adrenergic blocking agents and,
in appropriately selected patients, cardiac resynch-
ronization therapy (CRT) (13,14). Whether the sub-
sequent decrease in MR, however, contributes to
the symptomatic improvement and enhanced sur-
vival associated with such therapies is unclear.
Thus, the role of interventions directly targeting
reduction in MR has not been established, and
current guidelines recommend consideration for
mitral valve surgery for secondary MR only in pa-
tients who remain symptomatic after implementa-
tion of guidelines-directed medical therapy (GDMT)
or those with severe MR undergoing coronary artery
bypass surgery (1,2). In patients who remain symp-
tomatic despite GDMT and CRT, transcatheter mitral
valve repair has been shown to improve symptoms
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4 Bonow
A U G U S T 2 0 1 4 : 8 8 2 – 4 Treatment of Secondary Mitral Regurgitation
883(15), but improvement in survival has not been
established.
Against this backdrop, the report by Swaans et al.
(16) in this issue of JACC: Cardiovascular Interventions
provides new insights into the potential survival
beneﬁts of mitral valve intervention (both surgical
and transcatheter) compared with medical therapy in
patients with LV dysfunction and secondary MR. This
study was not designed speciﬁcally to address this
issue, because it included a broad spectrum of high-
risk patients with both primary and secondary forms
of MR. In this regard, the study population is similar
to previous reports of transcatheter mitral repair in
high-risk cohorts (17,18) in which the “high-risk”
patients are a conglomeration of those with primary
degenerative MR with reparable valves, but extensive
comorbid medical conditions that increase the risk of
surgery, and those with heart failure and secondary
MR in whom the LV dysfunction contributes further
to the assessment of high surgical risk. The apples
and oranges of this patient admixture create un-
certainties in attempts to fully interpret the data in
previous studies, as well as in the current study.
However, because the majority of patients studied by
Swaans et al. (16) had functional MR, with several
others deemed to have “mixed” functional plus
degenerative MR, the results do potentially address
the ongoing issues regarding when to intervene in
secondary, functional MR.
Swaans et al. (16) report enhanced survival with
mitral valve intervention (surgical repair or replace-
ment and transcatheter clip repair) compared with
medical management in patients with severe (3þ to
4þ) MR who were considered to be at high risk for
surgical treatment. High risk was determined by a log
euroSCORE $20 (19) or a combination of additional
clinical factors. Consistent with previous reports (20),
the survival of patients treated with transcatheter
therapy was equivalent to that of patients treated
surgically. Do these results move us closer to objec-
tive indications for mitral valve repair in high-risk
patients with either primary degenerative or sec-
ondary functional MR?
Limitations to keep in mind in assessing the cur-
rent results include the use of historical control pa-
tients as the conservative medically treated group
rather than a contemporaneous control group. The
medical management of those treated conservatively
is not speciﬁed, and thus it is impossible to know how
many actually received appropriate GDMT. The very
high mortality rate of the conservative group (one-
third died in the ﬁrst year) does raise the question
of aggressiveness of medical management; and if
there was undertreatment of these patients, theresults showing better outcome with surgical or
transcatheter intervention are self-fulﬁlling. The
conservatively treated group also had important
baseline differences compared with the other groups.
The conservatively treated patients had lower ejec-
tion fractions than those treated surgically and had
undergone fewer previous revascularization pro-
cedures than the transcatheter group (despite a
higher prevalence of concomitant coronary artery
disease) as well as fewer CRT procedures, and these
difference may have contributed to their higher
mortality. To account for these important baseline
differences, the authors performed propensity
weighting, which may or may not have fully adjusted
for the differences, as well as propensity matching of
a smaller sample of 81 triplets (presumably 27 in each
group). Analysis of these adjusted data continued to
show signiﬁcantly lower mortality in the trans-
catheter group compared with the control group.
The magnitude of this effect is not clear because the
survival curves in Figure 1 show outcomes for all
patients, not the matched patients.
As noted previously, analyzing survival data for
MR interventions in a combined group of patients
with primary and secondary MR is fraught with dif-
ﬁculty. It is anticipated that eliminating or reducing
MR would beneﬁt high-risk patients with primary MR,
which has previously been shown by Lim et al. (21) in
the pooled transcatheter data from the EVEREST II
(Endovascular Valve Edge-to-Edge Repair) High Risk
registry and the REALISM (Real World Expanded
Multi-center Study of the MitraClip System)
Continued Access registry in patients with degener-
ative MR with high surgical risk (STS score $8). This
experience has led to the current Food and Drug
Administration approval of the transcatheter device
for high-risk patients with degenerative MR.
What remains unknown is whether reducing MR
with surgery or transcatheter therapy beneﬁts high-
risk patients with secondary functional MR, which
currently is the leading use of the transcatheter de-
vice in Europe (18). When Swaans et al. (16) conﬁned
their analysis to only patients with functional MR, the
difference in survival between transcatheter and
conservative groups was less signiﬁcant (p ¼ 0.03),
and between surgically treated and conservative
groups, the difference was no longer signiﬁcant (p ¼
0.57). Importantly, it appears that this was an unad-
justed analysis that did not account for the baseline
risks among groups. Thus, the current data do not
deﬁne the role of mitral valve intervention in sec-
ondary MR. These data do underscore the need
for prospectively designed clinical trials of mitral
valve intervention (surgical or transcatheter) versus
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884GDMT in patients with LV dysfunction and secondary
MR. Trials emanating from the National Heart, Lung,
and Blood Institute Cardiothoracic Surgical Trials
Network (12,22) will help deﬁne surgical approaches
to patients undergoing surgery, but will not provide a
medically treated comparative group to determine
which patients should be referred for intervention. It
is the currently enrolling trials of transcatheter valve
repair versus medical management (COAPT [Cardio-
vascular Outcomes Assessment of the MitraClip
Therapy Percutaneous Therapy for High Surgical Risk
Patients] and RESHAPE-HF [A Randomized Study of
the MitraClip Device in Heart Failure Patients WithClinically Signiﬁcant Functional Mitral Regurgitation],
ClinicalTrials.gov identiﬁers NCT01626079 and
NCT01772108, respectively) that have the potential to
ﬁnally clarify whether targeting the mitral valve in
addition to GDMT results in improved outcomes of
patients with LV dysfunction and secondary MR.
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